242 related articles for article (PubMed ID: 15471200)
1. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
Scheithauer W; Blum J
Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
3. Management of hand-foot syndrome in patients treated with capecitabine (Xeloda).
Lassere Y; Hoff P
Eur J Oncol Nurs; 2004; 8 Suppl 1():S31-40. PubMed ID: 15341880
[TBL] [Abstract][Full Text] [Related]
4. The use of capecitabine in cancer: management of the hand foot syndrome.
Sudoyo AW
Acta Med Indones; 2005; 37(3):174-6. PubMed ID: 16110178
[No Abstract] [Full Text] [Related]
5. [Assessment of hand-foot syndrome in cancer patients treated with capecitabine-containing chemotherapy].
Yamagiwa K; Shigematsu T; Takeda K; Shirai M; Amemori K; Sunda K; Koike C; Yamada T
Gan To Kagaku Ryoho; 2013 Dec; 40 Suppl 2():161-3. PubMed ID: 24712132
[TBL] [Abstract][Full Text] [Related]
6. Dose-adjusting capecitabine minimizes adverse effects while maintaining efficacy: a retrospective review of capecitabine for metastatic breast cancer.
Leonard R; Hennessy BT; Blum JL; O'Shaughnessy J
Clin Breast Cancer; 2011 Dec; 11(6):349-56. PubMed ID: 21856245
[TBL] [Abstract][Full Text] [Related]
7. Management of hand-foot syndrome induced by capecitabine.
Gressett SM; Stanford BL; Hardwicke F
J Oncol Pharm Pract; 2006 Sep; 12(3):131-41. PubMed ID: 17022868
[TBL] [Abstract][Full Text] [Related]
8. [Capecitabine].
Yamaguchi K; Shimamura T; Tada M
Gan To Kagaku Ryoho; 2006 Jul; 33(7):891-5. PubMed ID: 16835474
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
10. Impact of prophylactic pyridoxine on occurrence of hand-foot syndrome in patients receiving capecitabine for advanced or metastatic breast cancer.
Yoshimoto N; Yamashita T; Fujita T; Hayashi H; Tsunoda N; Kimura M; Tsuzuki N; Yamashita H; Toyama T; Kondo N; Iwata H
Breast Cancer; 2010 Oct; 17(4):298-302. PubMed ID: 19789949
[TBL] [Abstract][Full Text] [Related]
11. [Unilateral acral necrosis as a minor form of hand-foot syndrome. Patient with unilateral acral necrosis secondary to capecitabine therapy for metastatic breast cancer].
Sauter C; Saborowski A; Ockenfels HM
Hautarzt; 2007 Jul; 58(7):619-22. PubMed ID: 17066280
[TBL] [Abstract][Full Text] [Related]
12. Capecitabine and PPE syndrome: a case report.
LoRusso PM
Breast J; 2003; 9(1):64-5. PubMed ID: 12558679
[No Abstract] [Full Text] [Related]
13. [Adverse events in patients treated with capecitabine as adjuvant chemotherapy after surgery for colorectal cancer--countermeasures against hand-foot syndrome].
Suto T; Ishiyama K; Yabuki H; Mori N; Inoue K; Chiba M; Igawa A; Watanabe T; Fujimoto H; Suzuki Y; Sugawara M; Saito T; Kobayashi Y; Matsuda M; Ikeda E; Sato T; Iizawa H
Gan To Kagaku Ryoho; 2010 Sep; 37(9):1729-33. PubMed ID: 20841936
[TBL] [Abstract][Full Text] [Related]
14. Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda).
Marsé H; Van Cutsem E; Grothey A; Valverde S
Eur J Oncol Nurs; 2004; 8 Suppl 1():S16-30. PubMed ID: 15341879
[TBL] [Abstract][Full Text] [Related]
15. Pooled analysis of individual patient data from capecitabine monotherapy clinical trials in locally advanced or metastatic breast cancer.
Blum JL; Barrios CH; Feldman N; Verma S; McKenna EF; Lee LF; Scotto N; Gralow J
Breast Cancer Res Treat; 2012 Dec; 136(3):777-88. PubMed ID: 23104222
[TBL] [Abstract][Full Text] [Related]
16. Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction.
Kara IO; Sahin B; Erkisi M
Breast; 2006 Jun; 15(3):414-24. PubMed ID: 16188440
[TBL] [Abstract][Full Text] [Related]
17. Development of and clinical experience with capecitabine (Xeloda) in the treatment of solid tumours.
Sternberg CN; Reichardt P; Holland M
Eur J Oncol Nurs; 2004; 8 Suppl 1():S4-15. PubMed ID: 15341878
[TBL] [Abstract][Full Text] [Related]
18. [Oral capecitabine as postoperative adjuvant chemotherapy in stage III colon cancer patients].
Yamaguchi T; Fukuda M; Yasui H; Okazaki S; Kubo K; Tanaka M; Une Y; Setoguchi Y; Hanada K; Moriyama S; Tani M; Murakami T; Okuchi Y; Ogiso S; Hata H; Sakata S; Otani T; Yamato T; Ikai I
Gan To Kagaku Ryoho; 2012 Mar; 39(3):389-93. PubMed ID: 22421765
[TBL] [Abstract][Full Text] [Related]
19. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
[TBL] [Abstract][Full Text] [Related]
20. Capecitabine (Xeloda) as monotherapy in advanced breast and colorectal cancer: effectiveness and side-effects.
Stathopoulos GP; Koutantos J; Lazaki H; Rigatos SK; Stathopoulos J; Deliconstantinos G
Anticancer Res; 2007; 27(3B):1653-6. PubMed ID: 17595791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]